-
Mashup Score: 3ALASCCA: adjuvant aspirin in colorectal cancer - 12 day(s) ago
The randomized ALASCCA trial (NCT02647099) investigated the effect of low-dose aspirin in patients with stage II and III colorectal cancer and PIK3CA mutations. Anna Martling, MD, PhD, Karolinska Institutet, Stockholm, Sweden, describes how a large cohort of patients genetic mutations within the PIK3CA signaling pathway were given either aspirin or placebo. In summer 2024, the trial met its primary endpoint, demonstrating a significant reduction in recurrence in the PIK3CA-mutated group, with an even stronger effect in patients with other mutations in the same signal pathway. These results were consistent across several subgroups, warranting further scientific evaluation. This interview took place at the ASCO GI Cancers Symposium 2025 in San Francisco, CA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0VJOncology – The video journal of oncology - 13 day(s) ago
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the awareness and understanding of oncology
Source: www.vjoncology.comCategories: General Medicine News, Onc News and JournalsTweet-
📢1 week until all things GI cancer are debated virtually at #GDUGI2023! Keep an eye on https://t.co/ys1d8pDAKO for all the updates…💻 @GreatDebatesCME #GDUGI2023 #CRCSM #PancSM #ESOCSM #STCSM #HPBCSM https://t.co/Bj1V9ui2l2
-
-
Mashup Score: 0VJOncology – The video journal of oncology - 13 day(s) ago
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the awareness and understanding of oncology
Source: www.vjoncology.comCategories: General Medicine News, Onc News and JournalsTweet-
📢1 week until all things GI cancer are debated virtually at #GDUGI2023! Keep an eye on https://t.co/ys1d8pDAKO for all the updates…💻 @GreatDebatesCME #GDUGI2023 #CRCSM #PancSM #ESOCSM #STCSM #HPBCSM https://t.co/Bj1V9ui2l2
-
-
Mashup Score: 6
Antonio D’Alessio, MD, Imperial College London, London, UK, explores the role of pathological response for predicting relapse-free survival in patients with early-stage hepatocellular carcinoma (HCC) treated with neoadjuvant immunotherapy. Pathological response, particularly complete and major pathological responses, was more strongly associated with relapse-free survival than radiological response, and a notable discrepancy between radiological and pathological responses was also reported. These findings highlight the need for standardized criteria to measure pathological response, which will be essential for the design of future clinical trials in this setting. This interview took place at the ASCO GI Cancers Symposium 2025 in San Francisco, CA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: General Medicine News, Oncologists1Tweet-
🎥@A_DAlessioMD of @imperialcollege discusses the stronger association of pathological response with relapse-free survival in early-stage HCC treated with neoadjuvant IO: ➡️https://t.co/aslhzv4Zcy⬅️ @ASCO #GI25 #HPBCsm #ImmunoOnc
-
-
Mashup Score: 10FOLFIRI-ramucirumab vs ramucirumab-paclitaxel in the 2L for upper gastrointestinal cancer - 14 day(s) ago
Timothy Brown, MD, UT Southwestern Medical Center, Dallas, TX, comments on the efficacy of FOLFIRI with ramucirumab compared to ramucirumab and paclitaxel in the treatment of upper GI cancers. Dr Brown highlights that a nationwide cohort analysis using the Flatiron Health database found no statistical difference in overall survival between the two regimens, suggesting that FOLFIRI with ramucirumab may be an equivocal alternative to ramucirumab and paclitaxel. This interview took place at the ASCO GI Cancers Symposium 2025 in San Francisco, CA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: General Medicine News, Oncologists1Tweet-
🎥@TimothyJBrownMD of @UTSWMedCenter discusses a Flatiron Health database analysis comparing FOLFIRI + ramucirumab vs. ramucirumab + paclitaxel in upper GI cancers, showing no significant survival difference: ➡️https://t.co/MByZ7WAqOB⬅️ @asco #GI25 #ImmunoOnc #STCsm
-
-
Mashup Score: 2Real-world safety of trastuzumab deruxtecan in Japanese patients with gastric cancer - 15 day(s) ago
Hisato Kawakami, MD, PhD, Tohoku University, Sendai, Japan, comments on the real-world incidence of interstitial lung disease (ILD) and severe adverse events associated with trastuzumab deruxtecan in Japanese patients with HER2-positive gastric cancer. Dr Kawakami notes that a post-marketing survey study of over 1,000 patients found an ILD incidence of 9.6% and severe adverse events of 2.3%, with a potential risk factor for ILD, including older age and prior lung disease. This interview took place at the ASCO GI Cancers Symposium 2025 in San Francisco, CA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: General Medicine News, Oncologists1Tweet-
🎥Hisato Kawakami, MD, PhD, of @TohokuUniPR discusses real-world data on interstitial lung disease (ILD) in Japanese patients with HER2-positive gastric cancer treated with trastuzumab deruxtecan: ➡️https://t.co/nniK3wAU3r⬅️ @asco #GI25 #STCsm #ImmunoOnc
-
-
Mashup Score: 0PREEMPT CRC: blood-based test for colorectal cancer screening - 16 day(s) ago
Aasma Shaukat, MD, MPH, NYU Grossman School of Medicine, New York, NY, discusses the results of PREEMPT CRC (NCT04369053), a large population-based study on a novel blood test for detecting colorectal cancer. Dr Shaukat notes that the study, conducted at 200 centers across the US, met all its primary endpoints, demonstrating the clinical validity of the blood test. The study’s findings show that the blood test has a high sensitivity and specificity for detecting colorectal cancer, with a positive predictive value of 15.5% for advanced colorectal neoplasia This interview took place at the ASCO GI Cancers Symposium 2025 in San Francisco, CA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: General Medicine News, Oncologists1Tweet-
🎥@AasmaShaukatMD of @nyugrossman shares PREEMPT CRC trial results validating a novel blood test for colorectal cancer detection, showing high sensitivity & specificity: ➡️https://t.co/jQCJMxB3au⬅️ @ASCO #GI25 #CRCSM #CTSM #TrialUpdate
-
-
Mashup Score: 0VJOncology – The video journal of oncology - 16 day(s) ago
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the awareness and understanding of oncology
Source: www.vjoncology.comCategories: General Medicine News, Onc News and JournalsTweet-
📢1 week until all things GI cancer are debated virtually at #GDUGI2023! Keep an eye on https://t.co/ys1d8pDAKO for all the updates…💻 @GreatDebatesCME #GDUGI2023 #CRCSM #PancSM #ESOCSM #STCSM #HPBCSM https://t.co/Bj1V9ui2l2
-
-
Mashup Score: 2
Alexander Spira, MD, PhD, Virginia Cancer Specialist, Fairfax, VA, comments on the value of cell-free DNA (ctDNA) as a biomarker in pancreatic cancer, highlighting its potential for monitoring patients and predicting response to treatment before undergoing CT scans. Dr Spira notes that while response rates may be lower than in other tumor types, the presence of ctDNA in stable disease patients suggests that tumors are still responding to treatment, and this may ultimately translate to improved progression-free and overall survival outcomes. This interview took place at the ASCO GI Cancers Symposium 2025 in San Francisco, CA This interview took place at the ASCO GI Cancers Symposium 2025 in San Francisco, CA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: General Medicine News, Oncologists1Tweet-
🎥@AlexSpiraMDPhD of @VCSpecialists highlights ctDNA as a biomarker in pancreatic cancer, aiding early response prediction before CT scans and potentially improving survival outcomes: ➡️https://t.co/lRGgsuxctH⬅️ @asco #GI25 #Pancsm #PancreaticCancer
-
-
Mashup Score: 2
Anna Martling, MD, PhD, Karolinska Institutet, Stockholm, Sweden, chronicles the historical use of aspirin in medicine and previous observations during cardiovascular studies which alluded to aspirin’s role in the prevention of colorectal cancer reoccurrence. Randomized controlled trials have shown that aspirin decrease both the number and size of bowel polyps. Additionally, retrospective research indicates the potential of aspirin for lowering colorectal cancer reoccurrence risk. The ALASCCA trial (NCT02647099) investigates aspirin’s link to the PIK3CA genetic biomarker as a predictive factor in treating colorectal cancer. This interview took place at the ASCO GI Cancers Symposium 2025 in San Francisco, CA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: General Medicine News, Oncologists1Tweet-
🎥@Annamartling of @karolinskainst discusses aspirin’s potential in colorectal cancer prevention and recurrence, with the ALASCCA trial exploring its link to the PIK3CA biomarker: ➡️https://t.co/wlMOlSuSfg⬅️ @ASCO #GI25 #CTSM #TrialUpdate
-
🎥@Annamartling of @karolinskainst shares ALASCCA trial results showing low-dose aspirin reduces recurrence in PIK3CA-mutated stage II/III colorectal cancer: ➡️https://t.co/22tUsXHdR0⬅️ @ASCO #GI25 #CRCSM #CTSM #TrialUpdate